Dudediligence.

Omeros Corporation

OMERNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

72.1M

on 2026-06-30, from 57.9M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

No limit

S-3ASR of 2025-11-14. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗

$150.0M

Cantor Fitzgerald, agreement of 2025-11-14. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

None

Priced warrants: none left. 10-Q ↗

Cash

7.7 quarters

$132.0M on 2026-06-30 ÷ $17.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-07-24Public offering5,365,853not readnot read424B5 ↗
2025-07-24Registered direct offering5,365,853$4.10$22.0M8-K ↗